Tong Ren Tang Technologies Co. Ltd. (TGRNF)
USD 0.69
(0.0%)
USD 0.69
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.11 Billion CNY | -7.99% |
| 2022 | 1.21 Billion CNY | 12.38% |
| 2021 | 1.07 Billion CNY | 14.41% |
| 2020 | 943.54 Million CNY | 2.77% |
| 2019 | 918.14 Million CNY | -22.91% |
| 2018 | 1.19 Billion CNY | 1.98% |
| 2017 | 1.16 Billion CNY | 15.95% |
| 2016 | 1 Billion CNY | 14.33% |
| 2015 | 880.96 Million CNY | 23.8% |
| 2014 | 711.61 Million CNY | 17.33% |
| 2013 | 606.48 Million CNY | 26.11% |
| 2012 | 480.91 Million CNY | 44.66% |
| 2011 | 332.45 Million CNY | 26.56% |
| 2010 | 262.67 Million CNY | 21.22% |
| 2009 | 216.7 Million CNY | 8.96% |
| 2008 | 198.89 Million CNY | 7.7% |
| 2007 | 184.66 Million CNY | 6.53% |
| 2006 | 173.34 Million CNY | -32.93% |
| 2005 | 258.44 Million CNY | 12.85% |
| 2004 | 229 Million CNY | 20.15% |
| 2003 | 190.59 Million CNY | 31.54% |
| 2002 | 144.89 Million CNY | 69.81% |
| 2001 | 85.32 Million CNY | 25.87% |
| 2000 | 67.79 Million CNY | 12.73% |
| 1999 | 60.13 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 87.68 Million USD | 0.0% |
| 2023 FY | 1.11 Billion CNY | -7.99% |
| 2023 Q2 | 92.4 Million USD | 0.0% |
| 2023 Q4 | 65.78 Million USD | 0.0% |
| 2022 Q4 | 93.79 Million USD | 0.0% |
| 2022 Q2 | 86.26 Million USD | 0.0% |
| 2022 FY | 1.21 Billion CNY | 12.38% |
| 2021 Q2 | 90.84 Million USD | 0.0% |
| 2021 FY | 1.07 Billion CNY | 14.41% |
| 2021 Q4 | 76.26 Million USD | 0.0% |
| 2020 FY | 943.54 Million CNY | 2.77% |
| 2020 Q4 | 68.81 Million USD | 0.0% |
| 2020 Q2 | 67.94 Million USD | 0.0% |
| 2019 Q2 | 102.25 Million USD | 0.0% |
| 2019 FY | 918.14 Million CNY | -22.91% |
| 2019 Q4 | 32.92 Million USD | 0.0% |
| 2018 FY | 1.19 Billion CNY | 1.98% |
| 2017 FY | 1.16 Billion CNY | 15.95% |
| 2016 FY | 1 Billion CNY | 14.33% |
| 2015 FY | 880.96 Million CNY | 23.8% |
| 2014 FY | 711.61 Million CNY | 17.33% |
| 2013 FY | 606.48 Million CNY | 26.11% |
| 2012 FY | 480.91 Million CNY | 44.66% |
| 2011 FY | 332.45 Million CNY | 26.56% |
| 2010 FY | 262.67 Million CNY | 21.22% |
| 2009 FY | 216.7 Million CNY | 8.96% |
| 2008 FY | 198.89 Million CNY | 7.7% |
| 2007 FY | 184.66 Million CNY | 6.53% |
| 2006 FY | 173.34 Million CNY | -32.93% |
| 2005 FY | 258.44 Million CNY | 12.85% |
| 2004 FY | 229 Million CNY | 20.15% |
| 2003 FY | 190.59 Million CNY | 31.54% |
| 2002 FY | 144.89 Million CNY | 69.81% |
| 2001 FY | 85.32 Million CNY | 25.87% |
| 2000 FY | 67.79 Million CNY | 12.73% |
| 1999 FY | 60.13 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 86.376% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 93.526% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 84.09% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 2909.355% |
| Novartis AG | 9.76 Billion USD | 88.574% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.969% |